The American Journal of Surgery
Volume 194, Issue 5 , Pages 594-599 , November 2007

Expression patterns of lymphangiogenic and angiogenic factors in a model of breast ductal carcinoma in situ

Presented at the 31st Annual Surgical Symposium of the Association of VA Surgeons, Little Rock, AR, May 10–12, 2007

  • Minghuan Yu, Ph.D., M.D.

      Affiliations

    • Department of Surgery, Wayne State University, 6C-UHC, 4201 St. Antoine, Detroit, MI 48201, USA
  • ,
  • Zhuo Tang, M.D.

      Affiliations

    • Department of Immunology, Wayne State University, 540 E. Canfield, Detroit, MI 48201, USA
  • ,
  • Sarah Alousi, B.A.

      Affiliations

    • Department of Surgery, Wayne State University, 6C-UHC, 4201 St. Antoine, Detroit, MI 48201, USA
  • ,
  • Richard S. Berk, Ph.D.

      Affiliations

    • Department of Immunology, Wayne State University, 540 E. Canfield, Detroit, MI 48201, USA
  • ,
  • Fred Miller, Ph.D.

      Affiliations

    • Breast Program, Karmanos Cancer Institute, 4100 John R, Detroit, MI 48201, USA
  • ,
  • Mary Ann Kosir, M.D.

      Affiliations

    • Department of Surgery, Wayne State University, 6C-UHC, 4201 St. Antoine, Detroit, MI 48201, USA
    • Breast Program, Karmanos Cancer Institute, 4100 John R, Detroit, MI 48201, USA
    • Surgical Service, John D. Dingell VA Medical Center, 4646 John R, Detroit, MI 48201, USA
    • Corresponding Author InformationCorresponding author. VAMC (11S)/Wayne State University, 4646 John R, Detroit, MI 48201. Tel.: +1-313-576-3970; fax: +1-313-576-1002.

Received 25 May 2007 ,Revised 12 July 2007

References 

  1. Cody HS. Sentinel lymph node biopsy for DCIS: Are we approaching consensus?. Ann Surg Oncol. 2007;14:2178–2181
  2. Maffuz A, Barroso-Bravo S, Najera I, et al. Tumor size as predictor of microinvasion, invasion, and axillary metastasis in ductal carcinoma in situ. J Exp Clin Cancer Res. 2006;25:223–227
  3. Yen TW, Hunt KK, Ross MI, et al. Predictors of invasive breast cancer in patients with an initial diagnosis of ductal carcinoma in situ: a guide to selective use of sentinel lymph node biopsy in management of ductal carcinoma in situ. J Am Coll Surg. 2005;200:516–526
  4. Tan JCC, McCready DR, Easson AM, et al. Role of sentinel lymph node biopsy inductal carcinoma-in-situ treated by mastectomy. Ann Surg Oncol. 2006;14:638–645
  5. Tait LR, Pauley RJ, Santner SJ, et al. Dynamic stromal-epithelial interactions during progression of MCF10DCIS.com xenografts. Int J Cancer. 2007;120:2127–2134
  6. Miller FR, Soule HD, Tait L, et al. Xenograft model of progressive human proliferative breast disease. J Natl Cancer Inst. 1993;85:1725–1732
  7. Arpino G, Laucirica R, Elledge RM. Premalignant and in situ breast disease: biology and clinical implications. Ann Intern Med. 2005;143:446–457
  8. Leonard GD, Swain SM. Ductal carcinoma in situ, complexities and challenges. J Natl Cancer Inst. 2004;96:906–920
  9. Achen MG, Mann GB, Sacher SA. Targeting lymphangiogenesis to prevent tumor metastasis. Br J Cancer. 2006;94:1355–1360
  10. Julian T, Fourchotte V, Anderson S, et al. Predictive factors that identify patients not requiring a sentinel node biopsy: continued analysis of the NSABP B-32 sentinel node trial. Poster presented at: San Antonio Breast Cancer Symposium; December 14–17, 2006; San Antonio, TX.
  11. Nakamura Y, Yasuoka H, Tsujimoto , et al. Flt-4-positive vessel density correlates with vascular endothelial growth factor-D expression, nodal status, and prognosis in breast cancer. Clin Cancer Res. 2003;9:5313–5317
  12. Wolfing P, Kersting C, Buerger H, et al. Expression patterns of angiogenic and lymphangiogenic factors in ductal breast carcinoma in situ. Br J Cancer. 2005;92:1720–1728
  13. Gotte M, Kersting C, Radke I, et al. An expression signature of syndecan-1 (CD138), E-cadherin and c-met is associated with factors of angiogenesis and lymphangiogenesis in ductal breast carcinoma in situ. Breast Cancer Res. 2007;9:R8;(doi;10.1186/bcr1641)
  14. Miller FR, Santner SJ, Tait L, Dawson PJ. MCF10DCIS.com xenograft model of human comedo ductal carcinoma in situ. J Natl Cancer Inst. 2000;92:1185–1186
  15. Miller FR. Xenograft models of premalignant breast disease. J Mam Gland Biol Neoplasia. 2000;5:379–391
  16. Jeltsch M, Kaipainen A, Joukov V, et al. Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. Science. 1997;276:1423–1425
  17. Stacker SA, Caesar C, Baldwin ME, et al. VEGF-D promotes the metastatic spread oftumor cells via the lymphatics. Nat Med. 2001;7:186–191
  18. Kaipainen A, Korhonen J, Mustonen T, et al. Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. Proc Natl Acad Sci U S A. 1995;92:3566–3570
  19. Valtaola R, Salven P, Heikkila P, et al. VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer. Am J Pathol. 1999;154:1381–1390
  20. Kitadai Y, Kodama M, Cho S, et al. Quantitative analysis of lymphangiogenic markers for predicting metastasis of human gastric carcinoma to lymph nodes. Int J Cancer. 2005;115:388–392
  21. Banerji S, Ni J, Wang SX, et al. LYVE-1, a new homologue of the CD44 glycoprotein, is a lymph-specific receptor for hyaluronan. J Cell Biol. 1999;144:789–801
  22. Skobe M, Hawighorst T, Jackson DG, et al. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med. 2001;7:192–198
  23. Mouta Carreira C, Nasser SM, di Tomaso E, et al. LYVE-1 is not restricted to the lymph vessels: expression in normal liver blood sinusoids and down-regulation in human liver cancer and cirrhosis. Cancer Res. 2001;61:8079–8084
  24. Chen L, Cursiefen C, Barabino S, et al. Novel expression and characterization of lymphatic vessel endothelial hyaluronate receptor 1 (LYVE-1) by conjunctival cells. Invest Ophthalmol Vis Sci. 2005;46:4536–4540
  25. Lee JY, Spicer AP. Hyaluronan: a multifunctional, megaDalton, stealth molecule. Curr Opin Cell Biol. 2000;12:581–586

PII: S0002-9610(07)00638-1

doi: 10.1016/j.amjsurg.2007.08.007

The American Journal of Surgery
Volume 194, Issue 5 , Pages 594-599 , November 2007